FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Instinct Bio Technical Company Holdings Inc. - Common stock
(NQ:
BIOT
)
0.3370
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Instinct Bio Technical Company Holdings Inc. - Common stock
BIOT Named Authorized Representative for IN01 Cancer Immunotherapy in Japan and China
September 30, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Instinct Bio Receives Nasdaq Notifications Regarding Minimum Bid Requirement and Minimum Market Value of Listed Securities and Publicly Held Shares
September 15, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives
September 04, 2026
Follow-up to the Company’s July 29, July 30 and August 10, 2026 announcements
From
Instinct Bio Technical Company Holdings Inc.
Via
GlobeNewswire
Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
August 10, 2026
From
Instinct Bio Technical Company Holdings Inc.
Via
GlobeNewswire
Instinct Bio Announces Strategic Collaboration With INVITRX to Expand GENREVER Into U.S. and Advance Indonesia Regenerative Medicine Initiatives
July 30, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference
August 01, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
June 03, 2022
Good morning! We're preparing for another busy day of trading with a breakdown of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference
May 18, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
May 16, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
April 04, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
March 24, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis
January 12, 2022
From
Blade Therapeutics, Inc.
Via
Business Wire
